_Services_Market.webp)
Next-Generation Sequencing (NGS) Services Market
Report ID: SQMIG35J2340
Report ID: SQMIG35J2340
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35J2340 |
Region:
Global |
Published Date: May, 2026
Pages:
157
|Tables:
134
|Figures:
77
Global Next-Generation Sequencing (NGS) Services Market size was valued at USD 12.5 Billion in 2024 and is poised to grow from USD 14.15 Billion in 2025 to USD 38.15 Billion by 2033, growing at a CAGR of 13.2% during the forecast period (2026-2033).
Rising adoption of precision medicine, growing demand for genomic research, declining sequencing costs, increasing prevalence of cancer and genetic disorders, and expanding applications of next-generation sequencing in clinical diagnostics are driving sales of next-generation sequencing (NGS) services.
In many cases, the hospitals, pharmaceutical companies, and public health entities have become dependent on specialized service providers who can provide clinical assays with compliance to high standards of accreditation and quality management. This development is likely to push the service providers to develop their capabilities in bioinformatics and improve their quality management process. On the other hand, applications of next-generation sequencing (NGS) such as companion diagnostics, non-invasive prenatal testing, pathogen monitoring, and rare disease identification are providing numerous market opportunities. Furthermore, applications such as liquid biopsy for targeted therapy and genomic surveillance systems for infectious disease outbreaks will open up new possibilities for the market. Growing demand for high-throughput genomic analysis and precision medicine is expected to primarily drive next-generation sequencing (NGS) services market growth. Advances in automated sample preparation, cloud-based analytics, and high-throughput sequencing platforms have further improved efficiency and reduced turnaround times, supporting broader clinical implementation.
On the contrary, high costs associated with advanced sequencing workflows, challenges related to genomic data interpretation and management, shortage of skilled bioinformatics professionals, and regulatory and reimbursement complexities are anticipated to slow down next-generation sequencing (NGS) services market penetration across the study period and beyond.
How is AI Improving Accuracy of Next-generation Sequencing (NGS) Service Workflows?
Artificial intelligence (AI) is improving the accuracy and efficiency of next-generation sequencing (NGS) services by enhancing data processing, reducing sequencing errors, and improving variant detection and interpretation. AI algorithms facilitate optimization of base calling and pattern recognition within the sequence to minimize both false-positive and false-negative outcomes. Deep learning-based tools for variant calling have demonstrated success in detecting variants that occur at low frequencies, a feature especially useful in oncology diagnostics and rare disease diagnostics. AI tools for quality control and automated interpretation are also assisting laboratories in producing more accurate and actionalizable results while minimizing analysis times. In summary, many NGS service providers are now adopting AI technology to increase efficiency in their operations.
Market snapshot - (2026-2033)
Global Market Size
USD 12.5 Billion
Largest Segment
Targeted Sequencing Services
Fastest Growth
Single-Cell Sequencing Services
Growth Rate
13.2% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global next-generation sequencing (NGS) services market is segmented by service type, workflow, application, end user, and region. Based on service type, the market is segmented into Whole Genome Sequencing (WGS) Services, Whole Exome Sequencing (WES) Services, targeted sequencing services, RNA Sequencing (RNA-Seq) services, single-cell sequencing services, epigenomics sequencing services, metagenomics sequencing services, de novo sequencing services, and others. Based on workflow, the market is segmented into sample preparation services, sequencing services, data analysis & bioinformatics services, and data storage & management services. Based on application, the market is segmented into oncology, reproductive health & prenatal testing, clinical diagnostics, infectious disease research, genetic & rare disease research, drug discovery & development, agricultural & animal research, microbiome analysis, forensics, and others. Based on end user, the market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals & diagnostic laboratories, contract research organizations (CROs), government & public health organizations, and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The Whole Genome Sequencing (WGS) services segment is anticipated to lead the global next-generation sequencing (NGS) services market revenue generation over the coming years. The extensive ability of whole-genome sequencing to capture genomic variations allows for the discovery of deep insights required in precision oncology. WGS offers an extensive ability to reveal structural changes and new biomarkers. This creates high demand from researchers and developers in clinical settings. Maturity in whole-genome sequencing platforms and bioinformatics workflows makes it possible to achieve reliable end-to-end workflows without requiring follow-up tests.
However, single-cell sequencing services is the most rapidly expanding segment as per this next-generation sequencing (NGS) services industry analysis. Increased interest in cell-by-cell resolution for tumor heterogeneity and immunology. Improvements in the field of microfluidics and analysis make it easier to develop new tests and mechanisms of action, which results in greater funding, leading to further expansion of the platforms in the NGS services market.
The data analysis & bioinformatics services segment is anticipated to account for the highest global next-generation sequencing (NGS) services market share. Interpreting the sequencing data into useful information for decision-making. The advanced pipeline, annotation, and validation services turn the raw sequencing data into useful information by making biomarker discovery, trial stratification, and regulatory submissions possible. Software development and integration of these services with laboratory procedures ensure that they become indispensable tools for widespread utilization of NGS technologies.
Nevertheless, data storage and management solutions offer the highest growth potential, as the increase in volume and regulatory pressure necessitates implementation of secure, scalable infrastructure solutions. Managed cloud-based services and audit-ready features simplify laboratory processes, facilitate collaboration, and open up opportunities for longitudinal studies, thereby expanding opportunities in next-generation sequencing technologies.
To get detailed segments analysis, Request a Free Sample Report
Advanced research infrastructure, concentrated service providers, and deep integration of sequencing into clinical and pharmaceutical workflows are helping this region hold sway over others. Strong collaborations between academic institutions, large healthcare systems, and industry expedite the use of more sophisticated genomic assays as well as increase the need for outsourcing sequencing services. A well-developed regulatory and reimbursement climate supports clinical applications; moreover, both substantial private and public reimbursements support development of platform innovation and specialized service offerings. Biotech clusters exist in dense patterns across the continent, with a workforce that is well-trained and capable enough to meet high demand through rapid scaling/capability, as well as provide customers with tailored solutions related to various research study designs. Comprehensive data analytics capabilities exist across the continent, and established sample repositories provide the foundation for North America’s global leadership position by creating a self-reinforcing ecosystem that attracts worldwide partnerships and outsourcing high-value genomic research.
Next-Generation Sequencing (NGS) Services Market in United States benefits from a dense concentration of clinical laboratories, large academic centers, and commercial providers demanding advanced sequencing services and workflows. Established collaborations between research institutions and industry enable complex trial support and diagnostic assay development. A skilled workforce and robust data infrastructure facilitate high-throughput processing and bioinformatics, while a competitive provider landscape fosters differentiation through specialized offerings and end to end integration.
Robust translational research networks and collaborative links between public healthcare institutions and academic centers are governing next-generation sequencing (NGS) services adoption in Canada. More commercial facilities join the ranks of the academically based laboratories to offer their services to international projects. Region-based sequencing centers offer particular services tailored to serve research in medicine as well as population genomics studies. The concern with quality, data handling, and institutional collaboration allows outsourcing possibilities to be considered.
Coordinated research networks, increasing integration of genomics into healthcare systems, and a vibrant contract research organization landscape that caters to multinational studies are helping generate new business scope. Cross-border cooperation and harmonization are essential to facilitate multi-center projects and the sharing of samples and data between jurisdictions. Investment in clinical genomics initiatives and in public-private partnerships has accelerated translation of sequencing assays into clinical workflows, while a highly skilled regulatory and scientific workforce supports adoption of complex workflows. The combination of different national strengths has resulted in complementary centers of excellence that provide a wide variety of specialized services related to high complexity diagnostic sequencing, bespoke bioinformatics, and other services positioning Europe as a flexible and collaborative hub for global genomic research and clinical trial sequencing requirements. The expansion of the commercial sequencing industries and strict regulatory environments related to quality and data protection promote confidence in the outsourcing of services, while increased partnership between the industries support the commercialization of assays and the diversification of service offerings across different markets.
Next-Generation Sequencing (NGS) services market in Germany is anchored by a robust diagnostics and pharmaceutical ecosystem that demands high quality, standardized sequencing services. Collaborative networks among university hospitals, research institutes, and specialized service providers enable complex clinical workflows and diagnostic validation. Emphasis on laboratory accreditation, engineering of automated processes, and strong industry partnerships supports scalable operations. The market benefits from a medtech base that fosters service innovation and competitive offerings.
Integrated healthcare genomics initiatives and a dynamic commercial services sector are helping shape adoption of next-generation sequencing (NGS) services in the United Kingdom. Expertise in regulation and clinical research helps to facilitate adoption and expand service offerings globally. Growth will be fueled by demands from clinical trial sponsors to sequence samples centrally and conduct expert bioinformatics analysis, coupled with strong partnerships between public research institutes and private organizations to validate newly developed assays.
Coordinated national genomics initiatives and growing interaction between academic research centers and innovative service providers are boosting demand for next-generation sequencing (NGS) services in France. Quality management and collaborations between the public sector and private companies increase service availability. With the development of new providers in the market, multi-center testing becomes possible. With regional sequencing services being offered, customized services are provided for translational research, as well as diagnostics development through bioinformatics expertise enhancement.
Strategic investments in laboratory capacity, homegrown service providers, and closer integration between industry and research institutions are helping generate new business scope in the region. In addition to supporting the establishment of regional sequencing hubs which provide competitive high volume processing and more advanced bioinformatics services through national initiatives and private sector expansion, they support building confidence in the credibility of the region by collaborating with global technology partners to improve operational efficiencies, scale laboratory automation, and develop adequately skilled technical teams who have had sufficient experience in conducting clinical trial sequencing and conducting translational research. They also help to improve both regulatory alignment and adherence to international standards of good quality, which improves trust between clinical sponsors and allows for more expansive cross-border collaborations.
Next-Generation Sequencing (NGS) Services Market in Japan is driven by advanced technical capabilities within research institutes and diagnostic laboratories. Partnerships between domestic technology firms, clinical centers, and service providers support development of validated assays and robust bioinformatics pipelines. Strong laboratory quality systems and process automation enable reliable sequencing offerings. A balanced regulatory approach combined with close industry collaboration fosters tailored solutions for clinical research and specialized diagnostic applications and care.
Next-Generation Sequencing (NGS) services demand in South Korea combines strong biotech capabilities with an agile commercial services sector that supports clinical and research sequencing needs. Focus on technology utilization, automation of laboratory procedures, and global quality standardization improves the credibility among international funding partners and stimulates diversity and exportability. High-level laboratories and networks of hospitals doing research, along with thriving bioinformatics firms, facilitate the creation of tailor-made workflow processes and data analysis solutions.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Expansion Of Clinical Applications
Technological Advancements In Platforms
High Operational And Compliance Costs
Data Privacy And Ethical Concerns
Request Free Customization of this report to help us to meet your business objectives.
Competitive landscape in the global NGS services market is driven by consolidation and strategic partnerships that reshape capacity and service differentiation. Private equity buyouts and targeted acquisitions are expanding lab capacity and pricing leverage. For example, ARCHIMED acquired SeqCenter and anacura acquired OHMX.bio. Providers also pursue platform diversification and instrument partnerships to win clinical and pharma contracts.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, high adoption of precision medicine, growing demand for genomic research, declining sequencing costs, and increasing prevalence of cancer and genetic disorders are anticipated to drive the demand for next-generation sequencing (NGS) services going forward. However, high costs associated with advanced sequencing workflows, challenges related to genomic data interpretation, and regulatory and reimbursement complexities are slated to slow down the adoption of next-generation sequencing (NGS) services in the future. North America is slated to spearhead the demand for next-generation sequencing (NGS) services owing to the presence of advanced healthcare infrastructure, strong investments in genomics research, and widespread adoption of precision medicine initiatives. Development of AI-powered genomic analysis platforms, integration of multimodal diagnostics, and increasing use of NGS in oncology, rare disease testing, and pathogen surveillance are anticipated to be key trends driving the next-generation sequencing (NGS) services sector over the coming years.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 12.5 Billion |
| Market size value in 2033 | USD 38.15 Billion |
| Growth Rate | 13.2% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Next-Generation Sequencing (NGS) Services Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Next-Generation Sequencing (NGS) Services Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Next-Generation Sequencing (NGS) Services Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Next-Generation Sequencing (NGS) Services Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Next-Generation Sequencing (Ngs) Services Market size was valued at USD 12.5 Billion in 2024 and is poised to grow from USD 14.15 Billion in 2025 to USD 38.15 Billion by 2033, growing at a CAGR of 13.2% during the forecast period (2026-2033).
Competitive landscape in the global NGS services market is driven by consolidation and strategic partnerships that reshape capacity and service differentiation. Private equity buyouts and targeted acquisitions are expanding lab capacity and pricing leverage. For example, ARCHIMED acquired SeqCenter and anacura acquired OHMX.bio. Providers also pursue platform diversification and instrument partnerships to win clinical and pharma contracts. 'Illumina', 'Thermo Fisher Scientific', 'QIAGEN', 'Eurofins Scientific', 'BGI Genomics', 'Macrogen', 'Azenta Life Sciences', 'Novogene', 'F. Hoffmann-La Roche', 'Pacific Biosciences', 'Oxford Nanopore Technologies', 'GENEWIZ', 'Personalis', 'Veracyte', 'Quest Diagnostics', 'Laboratory Corporation of America Holdings', 'SOPHiA GENETICS', '10x Genomics', 'Adaptive Biotechnologies', 'Natera'
Broadening clinical applications of next-generation sequencing, including precision oncology, rare disease diagnosis, and infectious disease surveillance, has expanded demand for specialized sequencing services. As more clinicians and diagnostic laboratories seek genomic insights to inform treatment selection and patient management, service providers are engaged to offer validated workflows, interpretive support, and regulatory compliance expertise. This practical alignment of clinical need with outsourced sequencing capabilities reduces barriers to adoption for healthcare institutions, encourages integration of NGS into care pathways, and sustains steady market growth through ongoing service utilization and collaboration.
Clinical Integration Acceleration: Clinical integration accelerates as sequencing services shift from research toward routine diagnostic workflows, enabling streamlined sample-to-result processes and collaboration with healthcare providers. Providers favor service partners offering standardized assays, clinical-grade reporting, and interoperability with electronic health records. This trend drives demand for validated pipelines, certified laboratories, and consultative support that translate genomic insights into actionable care decisions. Greater focus on turnaround time, result interpretability, and payer engagement positions sequencing services as integral components of personalized medicine delivery in care settings.
Why does North America Dominate the Global Next-Generation Sequencing (NGS) Services Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
